Indaptus Therapeutics (INDP) Common Equity (2020 - 2026)

Indaptus Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Common Equity fell 55.43% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 55.43% YoY), while the FY2025 annual figure was $3.2 million, down 20.11% from the prior year.
• Common Equity for Q1 2026 stood at $1.2 million, down from $3.2 million in the prior quarter.
• The five-year high for Common Equity was $33.4 million in Q1 2022, with the low at -$1.7 million in Q2 2025.
• The 5-year median for Common Equity is $9.4 million (2024), against an average of $12.9 million.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 4120.41% in 2022, then tumbled 127.14% in 2025.
• Indaptus Therapeutics' Common Equity stood at $24.6 million in 2022, then tumbled by 50.97% to $12.1 million in 2023, then plunged by 67.33% to $3.9 million in 2024, then declined by 20.11% to $3.2 million in 2025, then sank by 60.41% to $1.2 million in 2026.
• Business Quant data shows INDP's Common Equity at $1.2 million in Q1 2026, $3.2 million in Q4 2025, and $4.6 million in Q3 2025.